Abstract 1299P
Background
The purpose of this study was to evaluate the safety and efficacy of subsequent radiotherapy after first-line durvalumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC).
Methods
A total of 122 patients with ES-SCLC from three hospitals during July 2019 to December 2021 were retrospectively analyzed. Inverse probability of treatment weighting (IPTW) analysis was performed to address potential confounding factors. We primarily evaluated the progression-free survival (PFS) and overall survival (OS) in association with radiotherapy.
Results
After IPTW analysis, 49 patients received durvalumab plus chemotherapy with subsequent radiotherapy (Durva+EP+RT) and 72 patients received immunochemotherapy (Durva+EP). The median OS was 17.2 vs 12.3 months (hazard ratio (HR): 0.38; P=0.020), respectively, and the median PFS was 8.9 vs 5.9 months (HR: 0.56; P=0.030), respectively. Thoracic radiation therapy (TRT) resulted in longer OS (17.2 vs 14.7 months) and PFS (9.1 vs 7.2 months) compared to radiotherapy directed to other metastatic sites. Among patients with oligo-metastasis, radiotherapy also showed significant benefits, with a median OS of 17.4 vs 13.7 months and median PFS of 9.8 vs 5.9 months compared to no radiotherapy. Continuous durvalumab treatment beyond progression (TBP) prolonged OS compared to patients without TBP, in both the Durva+EP+RT (NA vs 15.8 months, HR: 0.48) and Durva+EP groups (12.3 vs 4.3 months, HR: 0.29). Grade 3 or 4 adverse events occurred in 13 (26.5%) and 13 (18.1%) patients, respectively, in the two groups; pneumonitis was mostly low-grade.
Conclusions
Addition of radiotherapy after first-line immunochemotherapy significantly improved survival outcomes with manageable toxicity in ES-SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Bethune-Cancer Radiotherapy Translational Medicine Research Fund of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
457P - Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting
Presenter: Gretchen Kimmick
Session: Poster session 04
458P - Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey
Presenter: Camilla Lisanti
Session: Poster session 04
460P - Impact of fulvestrant utilization on prognostic outcome among patients with HR+ve/HER2-ve metastatic breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 04
462P - Health outcomes of treatment sequences with eribulin or other single agents’ chemotherapy for treating relapsed metastatic HER2-negative breast cancer
Presenter: Simone Rivolo
Session: Poster session 04
463P - Impact of two waves of Sars-Cov-2 outbreak on the clinical presentation and outcomes of newly referred breast cancer cases at AP-HP: A retrospective multicenter cohort study
Presenter: Sonia Priou
Session: Poster session 04
464P - Developing a prognostic risk stratification model and treatment options for HER2-positive breast cancer brain metastasis
Presenter: JiaXin Chen
Session: Poster session 04
465P - Reporting of older subgroups enrolled to registration breast cancer trials, 2012-2021
Presenter: Colm Mac Eochagain
Session: Poster session 04